
    
      To evaluate the safety and the dose-response of ASP1517 on hemoglobin (Hb) correction when
      ASP1517 is applied intermittently in dialysis chronic kidney disease patients with anemia.

      To evaluate the treatment effect on Hb maintenance of ASP1517 administered intermittently in
      dialysis chronic kidney disease patients with anemia.
    
  